Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 
open-label randomized clinical trial

Grode, Leander; Ganoza, Christian A.; Brohm, Christiane; Weiner, January 3rd; Eisele, Bernd; Kaufmann, Stefan H. E.

doi:10.1016/j.vaccine.2012.12.053

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial

MPS-Authors

/persons/resource/persons81891

Ganoza, Christian A.
Department of Immunology, Max Planck Institute for Infection Biology, Max Planck Society;

/persons/resource/persons82210

Weiner, January 3rd
Department of Immunology, Max Planck Institute for Infection Biology, Max Planck Society;

/persons/resource/persons81969

Kaufmann, Stefan H. E.
Department of Immunology, Max Planck Institute for Infection Biology, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Grode, L., Ganoza, C. A., Brohm, C., Weiner, J. 3., Eisele, B., & Kaufmann, S. H. E. (2013). Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine, 31(9), 1340-1348. doi:10.1016/j.vaccine.2012.12.053.

Cite as: https://hdl.handle.net/11858/00-001M-0000-000E-F4FC-C

Abstract

There is no abstract available